Sample Submission Guidelines
Characterize the Model Before You Commit It to Sequencing
Organoid characterization asks a practical question: does the model preserve the particular features required for the next experiment? No single assay can answer that question for every model or application. A fit-for-purpose plan therefore links each evidence layer to a decision, such as confirming tissue organization, checking selected cell identities, comparing coding-region variants, or determining whether a passage is suitable for transcriptomic profiling.
Morphology can show whether an organoid forms an expected three-dimensional structure, but appearance alone does not establish lineage composition or genetic similarity. Marker staining can locate selected proteins, but it does not describe every cell state. Whole exome sequencing can compare coding-region variants, but it does not prove tissue architecture or expression-state equivalence. The value comes from choosing complementary methods whose limits are understood.
This page coordinates those methods at the project level. Detailed tissue processing and staining belong to our planned organoid histology and immunostaining services, while coding-region comparison belongs to the planned organoid exome sequencing service. Expression, cell-composition, and spatial questions are routed through our existing organoid sequencing services.
Select a Characterization Package Around the Research Question
The right package is determined by what the organoid must represent—not by adding every available test. We first define the biological feature, comparison, and downstream use. Each selected method must contribute evidence that changes how the model is interpreted or used.
| Research decision | Evidence that may be considered | What the evidence contributes | Important boundary |
|---|---|---|---|
| Does the model form the expected structure? | Bright-field morphology, H&E staining, section quality, architecture review | Shows organization, lumen formation, necrotic regions, or other model-relevant structural features, helping determine whether deeper molecular work is warranted | Structure does not establish cell identity, genetic fidelity, or function |
| Are selected lineages or states represented? | IHC, IF, or another model-appropriate marker method | Localizes selected proteins within the organoid, allowing the team to test a defined biological expectation rather than relying on shape alone | A marker panel evaluates selected targets; it is not a complete inventory of cell types or states |
| Is the material linked to the intended source or line? | Provenance review and an appropriate identity check | Supports traceability between submitted material, the cultured model, and downstream aliquots, reducing the risk of interpreting mislabeled or unrelated material | Identity confirmation does not establish phenotype or research suitability |
| Are relevant coding-region features retained? | Matched whole exome sequencing or another agreed DNA assay | Compares variants within the tested genomic scope, helping determine whether source-associated coding changes remain detectable | The conclusion is limited to the assay, samples, and analysis thresholds used |
| Are expression programs or cell populations appropriate for the study? | Bulk RNA sequencing, single-cell or single-nucleus RNA sequencing, or focused expression assays | Tests average expression, heterogeneity, or cell-state composition at the resolution required by the question | Dissociation, passage, maturation, and batch can influence the measured profile |
| Does tissue context matter to the interpretation? | Spatial transcriptomic or other spatially resolved analysis | Retains positional information so expression or cell states can be interpreted within the organoid structure | Spatial methods require compatible preservation, sectioning, and region-selection plans |
A smaller package is often more informative when its components directly answer the research question. Conversely, a single method is not the best choice when the intended conclusion spans several biological levels. If your decision depends on both architecture and coding-region fidelity, histology and exome evidence should be interpreted together rather than asking either method to stand in for the other.
What Each Evidence Layer Can—and Cannot—Tell You
Characterization becomes more reliable when every result is interpreted at the level it actually measures. We organize the report around evidence layers so reviewers can see which conclusions are directly supported, which remain provisional, and which require another method.
| Evidence layer | Best for | Not sufficient for | When another approach is more appropriate |
|---|---|---|---|
| Morphology and histology | Assessing visible organization and comparing selected structural features with a source or reference | Establishing complete molecular fidelity or resolving mixed cell populations | Add marker staining for localized cell identities; use sequencing when molecular differences drive the study |
| IHC or IF marker evidence | Locating selected proteins and testing a specific lineage or state hypothesis | Discovering all unexpected cell states or quantifying the full transcriptome | Use single-cell or single-nucleus profiling when cellular heterogeneity is the main unknown |
| Identity testing | Confirming that model and source records remain linked | Demonstrating structural, functional, or expression similarity | Combine with phenotype-specific evidence when model suitability is the decision |
| Whole exome sequencing | Comparing coding-region variants across matched materials | Capturing noncoding variation, tissue architecture, or current expression state | Use the appropriate genome, transcriptome, or spatial method when those features drive the conclusion |
| Bulk RNA sequencing | Comparing sample-average expression programs across conditions | Resolving which cell population produced a signal | Use cell-resolved profiling when shifts in cell composition could explain the average |
| Single-cell or single-nucleus RNA sequencing | Resolving cell populations, states, and heterogeneity | Preserving the original position of every measured cell | Use spatial profiling when location and microanatomy are central to interpretation |
| Spatial profiling | Linking molecular patterns to retained tissue context | Replacing all cell-level, histological, or genetic measurements | Combine with histology or cell-resolved data when morphology and cellular identity must be interpreted together |
Best for: an integrated characterization package is most useful when a downstream decision depends on more than one evidence layer—for example, whether a particular passage retains selected structure and coding-region features before sequencing.
Not for: if the only question is the presence of one predefined marker, a focused assay may be sufficient. If the key uncertainty is an unexpected cell population or spatially restricted expression pattern, a broader transcriptomic or spatial design is more appropriate than expanding a staining panel without a clear hypothesis.
Design the Right Comparison
A result becomes interpretable only when it is compared with the right reference. Characterization planning therefore begins with the experimental units and comparison groups: source tissue versus organoid, earlier versus later passage, independent batches, edited versus control lines, or treated versus untreated cultures. These relationships are defined before material is divided among assays.
A Project-Defined Characterization Workflow
- Define the decision. Specify which model feature must be supported and what downstream experiment depends on it. This keeps the package focused on evidence that can change the project decision.
- Review material and metadata. Confirm source, model type, passage, batch, culture history, controls, preservation state, and available matched material. This exposes missing context before an assay produces an ambiguous result.
- Select complementary evidence. Match structure, markers, identity, genetic evidence, or expression profiling to the decision. Each method is included because it addresses a different uncertainty.
- Allocate matched samples. Reserve material from defined culture points for each assay and downstream readout. This makes cross-method comparison more defensible than using unrelated aliquots collected at different stages.
- Perform testing and method-specific review. Evaluate assay quality and document exclusions or limitations. This prevents poor-quality material from being carried forward as if it were biological evidence.
- Integrate and route the results. Summarize what is supported, what remains uncertain, and whether additional characterization or sequencing is justified. The team receives a decision-oriented record rather than disconnected files.
Sample and Metadata Planning
Exact submission requirements depend on organoid type, assay combination, preservation route, and the condition of matched materials. The following table shows the information required for project review; quantities, containers, and shipping conditions are confirmed after feasibility assessment.
| Material or information | Why it is needed | Planning checks |
|---|---|---|
| Organoid material | Supplies the model aliquots for selected evidence layers | Model type, culture format, passage, batch, condition, preservation state, contamination history |
| Source tissue or source-derived reference | Enables direct comparison when the study asks whether source-associated features are retained | Availability, preservation compatibility, matched identifiers, tissue composition, assay suitability |
| Control model or baseline condition | Separates target biology from culture, editing, or treatment effects | Biological unit, control type, concurrent processing, batch relationship |
| Existing images or pathology information | Helps define structural expectations and regions that require closer evaluation | Imaging method, orientation, annotations, prior marker results, interpretation limits |
| Prior sequencing or genotype information | Supports assay selection and avoids repeating an analysis that cannot answer the current question | Data type, file availability, reference build, sample identity, coverage of the research question |
| Culture and passage records | Places morphology and molecular results in their experimental context | Media and matrix changes, passage history, recovery events, deviations, collection time point |
Human-source material requires appropriate collection permissions, de-identification, and transfer documentation supplied by the submitting organization. These requirements concern responsible research handling and do not expand the purpose of the service.
Compare Passage and Batch Effects Before Downstream Profiling
Passage and batch are not administrative labels; they are variables that can change how a characterization result should be read. Published organoid studies have shown that differentiation batch, maturation state, culture history, and cell composition can contribute substantial variation. Recording these factors allows the analysis to distinguish a planned biological comparison from a change introduced by model handling.
For tissue-derived organoids, we link source, line, passage, condition, and assay aliquot. For stem-cell-derived models, independent differentiations, clones, maturation stages, and concurrent controls may define the biological structure of the experiment. When several methods are used, samples are collected from aligned culture points wherever the design allows.
The goal is not to promise that variability disappears. It is to make the relevant sources of variation visible enough to support grouping, replication, and interpretation. If passage or batch is confounded with the primary condition, the report flags that limitation rather than assigning the difference to biology without qualification.
From Characterization Results to Sequencing Readiness
Sequencing readiness means more than having enough material. The selected batch, passage, preservation route, and comparison structure must also match the sequencing question. We use the characterization record to decide which material should proceed, what metadata must accompany it, and which readout can resolve the remaining uncertainty.
| Remaining research question | Sequencing direction | How characterization supports the decision |
|---|---|---|
| Are average expression programs different across models or conditions? | Bulk RNA sequencing | Defines the compared passages, batches, and structural context so expression differences are not interpreted without model history |
| Which cell populations or states account for the difference? | Single-cell or single-nucleus RNA sequencing | Uses marker and morphology evidence to form testable expectations while preserving the need for cell-resolved discovery |
| Where are expression programs located within the organoid? | Spatial profiling | Coordinates orientation, section selection, morphology, and region-level interpretation before spatial data are generated |
| Are selected coding-region variants retained across source and model? | Whole exome sequencing | Establishes matched identifiers and the exact comparison required for variant overlap or difference review |
| Do several evidence layers need to be coordinated across one study? | Integrated organoid research plan | Keeps assay allocation, sample identifiers, metadata, and interpretation connected across service modules |
Our organoid research solution provides the project-level framework when model work, characterization, sequencing, and interpretation must be coordinated. If the model itself still requires establishment, expansion, or banking, begin with organoid model development services. For a conventional coding-region workflow outside the organoid-specific package, review our whole exome sequencing service.
What You Receive
Deliverables are defined by the selected evidence layers and the downstream decision. A project may include an agreed sample map, method-specific quality records, representative morphology or staining images, identity or genetic comparison outputs, passage and batch context, sequencing-readiness notes, and an integrated findings summary. Raw and processed data are included when sequencing or quantitative analysis is part of the confirmed scope.
The integrated report distinguishes direct observations from interpretation. It records which samples were compared, what each method measured, what evidence supports the conclusion, and what the method cannot establish. This gives technical reviewers a traceable basis for deciding whether to proceed, repeat a comparison, or add a more informative readout.
Illustrative Organoid Characterization Results
These planned visuals explain typical result structures and are not customer data or performance claims.
Structure and Marker Comparison
A matched panel can place source tissue, organoid morphology, and selected marker localization side by side. The value is not visual similarity alone; the panel shows exactly which structural and protein-level observations were evaluated and where the comparison remains incomplete.
Coding-Region Variant Comparison
An illustrative overlap plot can organize shared and non-shared coding-region variants across source and organoid samples. The accompanying interpretation remains bounded by the assay and analysis scope, helping researchers avoid treating exome agreement as proof of complete model fidelity.
Passage and Batch Context
A passage-by-batch matrix can connect culture history with morphology, marker, or sequencing observations. This makes it easier to see whether a reported difference aligns with the intended experimental condition or with an unbalanced culture variable.
Organoid Characterization FAQs
Is organoid morphology enough to confirm model fidelity?
No. Morphology is useful for documenting growth and structure, but it does not establish lineage composition, genetic similarity, expression state, or function. The evidence package should match the conclusion required by the study.
Which characterization methods should I choose?
Start with the feature that must be supported and the decision that follows. Architecture questions may require histology, cell-identity questions may require selected markers or cell-resolved profiling, and coding-region questions may require exome sequencing. Methods are combined only when they answer distinct uncertainties.
Do I need matched source tissue?
Matched source material is valuable when the study asks whether source-associated features are retained. It may not be necessary for every developmental, engineered, or reference-line model. Availability, preservation, and assay compatibility are reviewed before the comparison is promised.
Can you compare different passages or batches?
Yes, when the material and design support a meaningful comparison. Passage, batch, culture condition, and collection time must be recorded, and biological replicates should not be confused with multiple wells from the same culture.
What can whole exome sequencing tell me about an organoid?
Whole exome sequencing can compare variants in protein-coding regions across matched materials. It does not assess all noncoding variation, tissue architecture, expression state, or every cell population, so its conclusion should be combined with other evidence when the research question spans those levels.
When should I use single-cell RNA sequencing instead of marker staining?
Marker staining is appropriate when the targets are predefined and their location matters. Single-cell or single-nucleus RNA sequencing is more informative when the main uncertainty is cellular heterogeneity, an unexpected population, or a broader cell-state landscape.
Can histology, exome sequencing, and transcriptomics use the same organoid sample?
These methods often require different preparation routes. We plan matched aliquots, culture points, and identifiers before testing so results can be compared without assuming that one physical sample can support every method.
What information should I provide for an initial project review?
Provide the organoid type and source, research question, passage and batch history, culture condition, available controls or matched tissue, prior characterization, planned downstream assay, and the decision you need the characterization results to support.
Case Study: Combining Histopathological and Genomic Evidence in Colorectal Tumor Organoids
Source. Esposito and colleagues reported an independent 2024 study in Cell Death & Disease that compared colorectal tumor organoids with their matched source tissues using multiple characterization layers.
Background. The researchers needed to determine which source-associated features remained represented after organoid establishment. A single visual or molecular measurement would not have been sufficient to describe the model, so the study combined tissue-level and genomic evidence.
Methods. Matched source tissues and organoids were evaluated with histopathological assessment, selected marker analysis, and genomic comparison. Figure 2 organized these evidence types around the same model-source relationship, allowing each method to answer a different part of the characterization question.
Results. The study reported that the organoid models retained selected histopathological and genomic characteristics of their corresponding source tissues. The evidence was presented across complementary measurements rather than as a universal fidelity score.
Conclusion. This case illustrates why organoid characterization should be designed around a defined comparison and interpreted layer by layer. It supports the use of combined structural, marker, and genomic evidence for research model assessment; it does not establish that every biological feature is preserved or that another organoid type will produce the same result.
Independent research figure from Esposito et al. (2024), Cell Death & Disease. Source: Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance. Reused under the Creative Commons Attribution 4.0 International License; only the research characterization evidence is discussed here.
References:
- Ahn S-J, et al. Essential Guidelines for Manufacturing and Application of Organoids. International Journal of Stem Cells. 2024;17(2):102-112.
- Lee H, et al. Standardization and quality assessment for human intestinal organoids. Frontiers in Cell and Developmental Biology. 2024;12:1383893.
- Phipson B, et al. Evaluation of variability in human kidney organoids. Nature Methods. 2019;16(1):79-87.
- Sandoval SO, et al. Rigor and reproducibility in human brain organoid research: Where we are and where we need to go. Stem Cell Reports. 2024;19(6):796-816.
- Esposito A, et al. Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance. Cell Death & Disease. 2024;15:878.
- VanDussen KL, et al. Guiding Principles: Reporting Elements for Gastrointestinal Organoid Research. Cellular and Molecular Gastroenterology and Hepatology. 2026;20(7):101772.